Omnisent has raised $3.0M in total across 1 funding round.
Omnisent's investors include Atlantic Labs, Prototype Capital.
Omniscient Neurotechnology (o8t™) is a technology company founded in 2019 that develops AI and data-driven solutions for personalized brain mapping and connectomics, revolutionizing brain care for neurosurgeons, researchers, and patients.[1][3][5] It builds software platforms that process conventional MRI scans using machine learning to generate hyperpersonalized brain maps, revealing unique neural connections to improve diagnosis and treatment of complex conditions like depression, Alzheimer’s, schizophrenia, and stroke, while providing predictive analytics and actionable surgical insights.[1][3][5] The company serves clinicians at hospitals worldwide and research institutions, addressing the limitations of one-size-fits-all brain atlases by enabling precision medicine, with growing adoption evidenced by multiple patents filed in 2025 and leadership from experts like Chief Medical Officer Michael Sughrue and Chief Data Scientist Stephane Doyen.[3][5]
Omniscient Neurotechnology was founded in 2019, emerging from the need to decode the brain's unique structural differences that make traditional mapping tools inadequate for individualized care.[1][3] The core idea stemmed from innovations in medical imaging, machine learning, and connectomics— the study of brain networks—to create personalized brain maps from standard MRI scans, unlocking insights previously shrouded in mystery.[1][5] Early traction came through partnerships with top global institutions, where the technology demonstrated rapid processing (e.g., full image analysis in under 2 hours with minimal manual input), saving time for surgeons and enabling better outcomes; pivotal moments include securing USPTO-issued patents and pre-IPO investment interest via platforms like EquityZen.[3][5]
Omniscient rides the wave of connectomics and precision neurology, where AI meets neuroimaging to tackle brain plasticity and individualized treatment amid rising neurological disorders affecting billions.[1][5] Timing is ideal with advances in machine learning enabling scalable MRI analysis, fueled by market forces like aging populations, mental health crises, and demand for non-invasive tools over outdated methods.[1][3][5] It influences the ecosystem by partnering with leading institutions, accelerating research into conditions like Alzheimer’s and stroke, and paving the way for AI-driven brain medicine that maximizes neuroplasticity for better global outcomes.[5]
Omniscient is poised to expand its platform with ongoing R&D and 2025 patents, potentially integrating more multimodal data for real-time clinical decisions and broader therapeutic applications.[3][5] Trends like AI democratization in healthcare and neurotech investments will propel growth, evolving its role from mapping pioneer to ecosystem leader in personalized brain care. As it scales pre-IPO, expect deeper impact on surgical precision and research breakthroughs, affirming that every brain truly can be better.[1][5]
Omnisent has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $3.0M Seed | Atlantic Labs, Prototype Capital |
